Status:
UNKNOWN
A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
Lead Sponsor:
Chinese PLA General Hospital
Collaborating Sponsors:
LinkDoc Technology (Beijing) Co. Ltd.
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Brief Summary
The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.
Detailed Description
The study is a real-world study and the case records of patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti...
Eligibility Criteria
Inclusion
- Pathologically or cytologically confirmed advanced solid tumors;
- Received anti-PD-1/PD-L1 antibody therapy.
Exclusion
- No specific exclusion criteria in this real world study.
Key Trial Info
Start Date :
December 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2019
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03787953
Start Date
December 30 2018
End Date
September 30 2019
Last Update
May 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, China, 100853